Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245301 | 0.93 | MEN1 (0.39) | CA1CA2CA7CA9TSHR | |
| SCHEMBL26483457 | 0.91 | CA1 (0.36) | CA1CA2CA7CA9TSHR | |
| SCHEMBL17471840 | 0.89 | CA1 (0.41) | CA1CA2CA7CA9 | |
| SCHEMBL19225068 | 0.85 | CA1 (0.39) | CA1CA2CA7CA9TSHR | |
| SCHEMBL6130679 | 0.84 | CA1 (0.36) | CA1CA2CA7CA9 | |
| SCHEMBL1357542 | 0.83 | TSHR (0.47) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL6130675 | 0.83 | CA1 (0.39) | CA1CA2CA7CA9 | |
| SCHEMBL19543524 | 0.81 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL14644928 | 0.81 | TSHR (0.45) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL5502602 | 0.81 | TSHR (0.45) | TSHRMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-23 | — | — | US | disclosed |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150025126-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-01-22 | — | — | US | disclosed |
| US-20130197210-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8277846-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120172525-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8092833-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-07-28 | — | — | US | disclosed |
| EP-1268584-B1 | COMPOSITIONS AND METHODS FOR SELECTIVELY BINDING AMINES OR AMINO ACID ENANTIOMERS OVER THEIR COUNTER-ENANTIOMERS | IBC ADVANCED TECH INC (US) | 2010-05-05 | — | — | EP | disclosed |
| US-20080279954-A1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7375096-B1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-06-07 | — | — | US | disclosed |
| US-7166302-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-01-23 | — | — | US | disclosed |
| US-6686479-B2 | SEPARATION OF ENANTIOMORPHS | IBC ADVANCED TECHNOLOGIES, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1268584-A4 | COMPOSITIONS AND METHODS FOR SELECTIVELY BINDING AMINES OR AMINO ACID ENANTIOMERS OVER THEIR COUNTER-ENANTIOMERS | IBC ADVANCED TECH INC (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1268584-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY BINDING AMINES OR AMINO ACID ENANTIOMERS OVER THEIR COUNTER-ENANTIOMERS | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020019491-A1 | Compositons and methods for selectively binding amines or amino acid enantiomers over their counter-enantiomers | IBC ADVANCED TECHNOLOGIES, INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001068729-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY BINDING AMINES OR AMINO ACID ENANTIOMERS OVER THEIR COUNTER-ENANTIOMERS | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025126-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | PICALM, IMMT, PAICS | CA1 1311/4885CA2 1898/4885CA7 915/4885 |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | CA1 1220/4885CA2 2078/4885CA7 1477/4885 |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | CA1 1220/4885CA2 2078/4885CA7 1477/4885 |
| US-20080279954-A1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | PICALM, IMMT, PAICS | CA1 1311/4885CA2 1898/4885CA7 915/4885 |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | CA1 1105/4885CA2 1992/4885CA7 1397/4885 |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | INTS6, EXOSC5, PCBP1 | CA1 1220/4885CA2 2078/4885CA7 1477/4885 |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | CA1 1105/4885CA2 1992/4885CA7 1397/4885 |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | CA1 1220/4885CA2 2078/4885CA7 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.